Clinical Efficacy of Immediate Radical Surgery for Locally Advanced Prostate Cancer

Wei WANG; Sheng LIU; Hongqing ZHOU; Mingsheng LIU; Pingbo XIE; Feng GUO; Guanyu CHEN

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > Accepted Manuscript

Wei WANG, Sheng LIU, Hongqing ZHOU, Mingsheng LIU, Pingbo XIE, Feng GUO, Guanyu CHEN. Clinical Efficacy of Immediate Radical Surgery for Locally Advanced Prostate Cancer[J]. Journal of Kunming Medical University.

Citation:

Wei WANG, Sheng LIU, Hongqing ZHOU, Mingsheng LIU, Pingbo XIE, Feng GUO, Guanyu CHEN. Clinical Efficacy of Immediate Radical Surgery for Locally Advanced Prostate Cancer[J]. Journal of Kunming Medical University.

Citation:

PDF( 635 KB)

Clinical Efficacy of Immediate Radical Surgery for Locally Advanced Prostate Cancer

1.
The second Ward of Urology，The First People's Hospital of Qujing City，Qujing Yunnan 655000
2.
Graduate School
3.
Clinical Skills Training Center，Kunming Medical University，Kunming Yunnan 650500，China

Received Date: 2024-09-30
Available Online: 2024-12-24

Abstract

Abstract

Objective To explore the clinical efficacy and safety of immediate laparoscopic radical prostatectomy immediately following the diagnosis of locally advanced prostate cancer. Methods A retrospective analysis was performed for 63 patients with locally advanced prostate cancer who met the inclusion criteria diagnosed in The 1st People's Hospital of Qujing City, Yunnan Province from January 2018 to January 2023. All patients were diagnosed via ultrasound-guided transperineal prostate biopsy. The experimental group consisted of 37 patients who underwent immediate laparoscopic radical prostatectomy after pathological diagnosis, followed by postoperative adjuvant hormone therapy. The control group included 26 patients who first received 3 months of neoadjuvant hormone therapy before undergoing radical surgery, followed by adjuvant hormone therapy postoperatively. The two groups were compared in terms of surgical duration, intraoperative blood loss, length of hospital stay, duration of catheterization, positive surgical margin rate, rectal injury, positive lymph node rate, incidence of urinary fistula and lymphatic leakage, changes in PSA level, postoperative urinary control, biochemical recurrence and distant metastasis. Results In the control group, serum PSA levels, prostate volume, and clinical staging significantly decreased after neoadjuvant hormon therapy. The positive surgical margin rate in the experimental group was significantly higher than that in the control group, with a statistically significant difference（P < 0.05）. There were no statistically significant differences between the two groups in terms of surgical duration, intraoperative blood loss, length of hospital stay, duration of catheterization, rectal injury, positive lymph node rate, incidence of urinary fistula and lymphatic leakage （P > 0.05）. Follow-up at 18 to 36 months revealed no statistically significant differences between the two groups in terms of serum PSA levels at one month post-surgery, complete urinary control rate at six months post-surgery, and biochemical recurrence and distant metastasis at one and two years post-surgery （P > 0.05）. Conclusion Immediate laparoscopic radical prostatectomy following the diagnosis of locally advanced prostate cancer is a clinically safe and feasible treatment option. Noadjuvant hormone therapy reduces tumor staging, lowers the positive surgical margin rate, significantly decreases prostate volume, and provides greater operational space without increasing surgical risks.
- Prostate cancer,
- Locally advanced prostate cancer,
- Noadjuvant hormonal therapy,
- Laparoscopic radical prostatectomy

FullText(HTML)

References(31)

References

[1]	Abudoubari S,Bu K,Mei Y,et al. Prostate cancer epidemiology and prognostic factors in the United States[J]. Front Oncol,2023,13:1142976. doi: 10.3389/fonc.2023.1142976
[2]	Sung H,Ferlay J,Siegel R L,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Ca-Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660
[3]	Kensler K H,Rebbeck T R. Cancer progress and priorities: Prostate cancer[J]. Cancer Epidem Biomar,2020,29(2):267-277. doi: 10.1158/1055-9965.EPI-19-0412
[4]	Trabzonlu L,Kulac I,Zheng Q,et al. Molecular pathology of high-grade prostatic intraepithelial neoplasia: Challenges and opportunities[J]. Cold Spring Harb Perspect Med,2019,9(4):a030403. doi: 10.1101/cshperspect.a030403
[5]	林豪胜,杨增士,叶宁. 基于年龄-时期-队列模型的中国前列腺癌发病死亡趋势分析[J]. 临床泌尿外科杂志,2024,39(8):708-712.
[6]	Vale C L,Fisher D,Kneebone A,et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data[J]. Lancet,2020,396(10260):1422-1431. doi: 10.1016/S0140-6736(20)31952-8
[7]	Ke Z,Xu Y,Shu Y,et al. Multivariate logistic regression analysis of the clinical factors influencing locally advanced prostate cancer[J]. Transl Cancer Res,2024,13(2):676-685. doi: 10.21037/tcr-23-1680
[8]	Zhang L,Zhao H,Wu B,et al. The impact of neoadjuvant hormone therapy on surgical and oncological outcomes for patients with prostate cancer before radical prostatectomy: A systematic review and meta-analysis[J]. Front Oncol,2020,10:615801.
[9]	Montie J E. Initial therapy with radical prostatectomy for high risk localized prostate cancer[J]. Journal of Urolgy,2006,176 (6 Pt 2): S27-S26.
[10]	冯春丽,周建于,段文越,等. 新辅助内分泌治疗对前列腺癌根治术疗效的影响研究[J]. 石河子科技,2021,4(1):54-57.
[11]	那彦群,叶章群,孙颖浩,等. 2014版中国泌尿外科疾病诊断治疗指南手册[M]. 北京: 人民卫生出版社,2013,125-127.
[12]	Wang Z,Ni Y,Chen J,et al. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: A systematic review and meta-analysis[J]. World Journal of Surgical Oncology,2020,18(1):42. doi: 10.1186/s12957-020-01824-9
[13]	Shelley M D,Kumar S,Wilt T,et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma[J]. Cancer Treatment Reviews,2009,35(1):9-17. doi: 10.1016/j.ctrv.2008.08.002
[14]	Joung J Y,Kim J E,Kim S H,et al. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer[J]. BMC Urology,2015,13(15):82.
[15]	Naiki T,Kawai N,Okamura T,et al. Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy[J]. BMC Urology,2012,12:36. doi: 10.1186/1471-2490-12-36
[16]	伍宏亮,汪盛,关翰. 新辅助内分泌治疗联合腹腔镜前列腺癌根治术对局部晚期前列腺癌的疗效分析[J]. 蚌埠医学院学报,2019,44(6):768-770.
[17]	胡凯强. 新辅助内分泌治疗联合腹腔镜前列腺癌根治术在高危前列腺癌治疗中临床研究[D]. 石家庄: 河北医科大学,2021.
[18]	李清,肖博,刘士军,等. 前列腺穿刺活检术后间隔时间对腹腔镜前列腺癌根治术的影响[J]. 北京大学学报(医学版),2014,46(4):532-536. doi: 10.3969/j.issn.1671-167X.2014.04.009
[19]	祝秀文,万里军,童炎岳,等. 前列腺穿刺活检术后间隔时间对腹腔镜前列腺癌根治术的影响[C]// 浙江省医学会泌尿外科学分会,浙江省医学会男科学分会. 2019年浙江省医学会泌尿外科学、男科学学术大会论文汇编. 衢州市人民医院;2019: 2.
[20]	蒋齐,杨刚,江斌,等. 不同径路前列腺穿刺活检对于前列腺癌根治手术过程影响的临床研究[J]. 临床泌尿外科杂志,2022,37(6):418-421.
[21]	Reisz P A,Laviana A A,Zhao Z,et al. Assessing the quality of surgical care for clinically localized prostate cancer: Results from the ceasar study[J]. Journal of Urology,2020,204(6):1236-1241. doi: 10.1097/JU.0000000000001198
[22]	Kim M,Yoo D,Pyo J,Cho W. Clinicopathological significances of positive surgical resection margin after radical prostatectomy for prostatic cancers: A meta-analysis[J]. Medicina Lithuania,2022,58(9):1251.
[23]	Cho S Y,Choi Y D. The effect of tumor-prostate ratio on biochemical recurrence after radical prostatectomy[J]. World Journal of Mens Health,2016,34(2):123-128. doi: 10.5534/wjmh.2016.34.2.123
[24]	Sun G,Liang Z,Jiang Y,et al. Clinical analysis of perioperative outcomes on neoadjuvant hormone therapy before laparoscopic and robot-assisted surgery for localized high-risk prostate cancer in a Chinese cohort[J]. Current Oncology,2022,29(11):8668-8676. doi: 10.3390/curroncol29110683
[25]	Hu J C,Hung S C,Ou Y C. Assessments of neoadjuvant hormone therapy followed by robotic-assisted radical prostatectomy for intermediate and high-risk prostate cancer[J]. Anticancer Research,2017,37(6):3143-3150.
[26]	张浩永,许方蕾. 前列腺癌患者根治术后尿失禁危险因素的meta分析[J]. 临床泌尿外科杂志,2024,39(8):713-718+724.
[27]	Kawase M,Goto T,Ebara S,et al. Nomogram predicting locally advanced prostate cancer in patients with clinically organ-confined disease who underwent robot-assisted radical prostatectomy: A retrospective multicenter cohort study in Japan (the MSUG94 group)[J]. Ann Surg Oncol,2023,30(11):6925-6933. doi: 10.1245/s10434-023-13747-2
[28]	Hsu C Y,Wildhagen M F,Van Poppel H,et al. Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy[J]. Bju Int,2009,105(11):1536-1540.
[29]	Tosco L,Laenen A,Briganti A,et al. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer[J]. Prostate Cancer and Prostatic Diseases,2017,20(4):407-412. doi: 10.1038/pcan.2017.29
[30]	Berglund R K,Tangen C M,Powell I J,et al. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: Update on southwest oncology group study 9109[J]. Urology,2012,79(3):633-637. doi: 10.1016/j.urology.2011.11.019
[31]	Roldan F L,Falagario U G,Olsson M,et al. Long-term oncological outcomes after multimodal treatment for locally advanced prostate cancer[J]. Bjui Compass,2024,5(9):885-892.

Relative Articles(20)

Relative Articles

[1]	Longguo DAI, Yu BAI. Research Progress of Cytoreductive Treatment for Metastatic Prostate Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230103
[2]	Pingbo XIE, Mingsheng LIU, Hongqing ZHOU, Shaomei WU, Tao SHAO, Feng GUO. Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20231208
[3]	Bin ZHAO, Yuanpeng DUAN, Guoying ZHANG, Chengwei BI, Libo YANG, Zhiyu SHI, Yong YANG, Jianpeng ZHANG, Ting GAO. CircRNA EZH2 Promotes Proliferation and Migration of Prostate Cancer Cells by Regulating miR-30c-5p. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220731
[4]	Sun Jian Wei , Wang Jian Song , Liu Zi Chao , Zheng Li Min . . Journal of Kunming Medical University,
[5]	Li Hui , Ping Qin Rong , Shi Yun Qiang , Wang Chun Hui , Yang Yang , Hu Li Bing , Bi Xiao Fang , Li Jian , Zhong Yi Ming . . Journal of Kunming Medical University,
[6]	Pang Yue Wen , Gong Hui Jie , Wang Ling , Shi Jing , Duan JunYao , Feng Ying Ying , Yan Yong Ji . . Journal of Kunming Medical University,
[7]	Ran Zhen , Zhu Yun Sha , Hai Bing , Zhang Jing Song . Relationship between the Proportion of Tumor Infiltrating Lymphocytes in Tumor Mass and Postoperative Recurrence of Prostate Carcinoma. Journal of Kunming Medical University,
[8]	Zhao Bin , Li Rui Qian , Zhang Guo Ying , Lei Yong Hong , Wang Qi Lin , Liu Zhi Min . Overexpression of miR-4328 Inhibits the Proliferation, Migration and Epithelial Mesenchymal Transition of Prostate Cancer Cells. Journal of Kunming Medical University,
[9]	Luo Sai Mei . . Journal of Kunming Medical University,
[10]	Ma Yin Rui . . Journal of Kunming Medical University,
[11]	Ke Kun Bin . . Journal of Kunming Medical University,
[12]	Zhang Jing Song . . Journal of Kunming Medical University,
[13]	Shen Hong . . Journal of Kunming Medical University,
[14]	Liu Xiao Dong . . Journal of Kunming Medical University,
[15]	Lei Jing . . Journal of Kunming Medical University,
[16]	Du Xiong . . Journal of Kunming Medical University,
[17]	Sun Jian Wei . . Journal of Kunming Medical University,
[18]	Liu Peng Jie . . Journal of Kunming Medical University,
[19]	Wu Jing . . Journal of Kunming Medical University,
[20]	. Value of Contrast-enhanced Ultrasound in Diagnosis of Prostate Cancer. Journal of Kunming Medical University,